Nilutamide is named as an intervention in 2 current clinical trials in our Switzerland, Mexico, Canada and Israel registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is SWOG Cancer Research Network (1). The most-studied condition is Castration Levels of Testosterone.
Of the three regulators tracked here, the first to approve Nilutamide was the US, on 19 Sep 1996.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
| Study | Phase | Status | Lead sponsor | Registers |
|---|
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
| Lead sponsor | Trials |
|---|---|
| SWOG Cancer Research Network | 1 |
| NRG Oncology | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Switzerland | 1 | 1 |
| Clinical trials in Mexico | 1 | 1 |
| Clinical trials in Canada | 1 | 0 |
| Clinical trials in Israel | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Switzerland, Mexico, Canada and Israel registers name Nilutamide (also registered as RU-23908) as a drug or biological intervention, as of the registry sync on 6 October 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Switzerland and 1 with sites in Mexico. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
SWOG Cancer Research Network (1) and NRG Oncology (1). The number in brackets is how many trials each organisation leads.
The registers we track list 1 entry for Nilutamide: US FDA: resolved. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Nilutamide works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nilutamide works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nilutamide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 6 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.
